Story excerpt provided by Crain’s Cleveland Business.
NeuroTherapia Inc., a Cleveland Clinic spinoff company, said it has received a $1.7 million commitment from the Alzheimer’s Drug Discovery Foundation to advance its NTRX-07 drug toward human clinical trials.
The therapy “targets a cannabinoid receptor in the brain, which is a new approach for treating Alzheimer’s and other neurologic diseases,” NeuroTherapia said in a news release.
Click here to read the complete article.
Originally published September 22, 2016.